Precision oncology applies genomic and other molecular analyses of tumor biopsies to improve the diagnosis and treatment of cancers. In addition to identifying therapeutic options, precision oncology tracks the response of a tumor to an intervention at the molecular level and detects drug resistance and the mechanisms by which it occurs. Integrative genomics can include sequencing specific panels of genes, exomes, or the entire triad of the patient's germline, tumor exome, and tumor transcriptome. Although the capabilities of sequencing technologies continue to improve, widespread adoption of genomicsdriven precision oncology in the clinic has been held back by logistical, regulatory, financial, and ethical considerations. Nevertheless, integrative clinical sequencing programs applied at the point of care have the potential to improve the clinical management of cancer patients. nature biotechnology VOLUME 36 NUMBER 1 JANUARY 2018 4 7 r e v i e w point for precision oncology 11, 12 . For example, in a clinical trial that featured sequencing of ten cancer genes in lung adenocarcinoma tissues from 733 patients, one or more oncogenic mutations were identified in 466 patients (64%), and 24 patients (3%) had mutations in two or more genes 13 . 260 patients received targeted therapy and achieved median survival of 3.5 years, compared with 2.4 years for 318 patients that did not receive matched therapy 14 .
The earliest documented examples of targeting the underlying mechanisms driving tumor growth to treat cancer might be George Beatson's treatment of breast cancer patients by oophorectomy in 1896 (ref. 1) , and Charles Huggins' use of castration to treat prostate cancer half a century later 2 . Although the mechanisms that underlie cancer have been investigated for more than 100 years, clinical management remains rooted in morphological and histopathological methods to diagnose and estimate prognosis, while treatments rely on surgery to remove tumors followed by chemo-and/or radiation therapy to stop uncontrolled cell proliferation 3, 4 .
Insights gained from the molecular characterization of aberrant genes, cell-surface markers, hormonal or endocrine mediators, and signaling pathways associated with cancer have been incorporated into diagnostic and treatment strategies (Fig. 1) . The application of targeted therapies matched to specific aberrations for some cancers [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , synthetic lethal targeting of DNA repair machinery in BRCA-deficient ovarian cancers 5 , and recent progress with immune checkpoint inhibitors in cancers with hypermutation and/or neo-antigen signatures 6 have collectively fueled optimism that identification of molecular targets in individual cancers to enable targeted therapeutics could represent a general paradigm for cancer care. This optimism has been tempered by inconsistent responses to targeted therapies and the emergence of drug resistance in many patients.
Over the past decade, multiple large-scale genomic studies have identified genomic, transcriptomic, and proteomic aberrations that are specific to one cancer type or common in different cancers. These findings have suggested to many researchers that clinical management of individual cancer patients should be routinely informed by comprehensive molecular analyses of their tumors. Fortunately, policy and funding have kept pace with science, as exemplified by the Precision Medicine Initiative (https://www.whitehouse.gov/precisionmedicine) 7, 8 and National Cancer Moonshot Initiative 9 .
Precision medicine initiatives are poised to transform the paradigm of population-based clinical studies to define treatments for average patients into biomarker-driven clinical trials to identify the best treatments for individual patients 10, 15 . Initial clinical efforts have mainly focused on sequencing panels of well-validated therapeutic target genes, and have gradually expanded to include broader panels of cancer-associated genes. Less frequently, efforts have focused on performing whole-exome sequencing or comprehensive, integrative sequencing, encompassing germline, genomic, and transcriptomic sequencing (Fig. 2) .
Here, we review the application of precision oncology by sequencing gene panels, the use of whole-exome capture or genome sequencing, as well as RNA sequencing, in clinical trials and routine clinical practice. We also outline analytical setup and operational workflow of current integrative clinical sequencing programs. This is followed by a brief discussion of salient issues and directions for future developments.
Sequencing of gene panels for precision therapeutics
Specific aberrations in ~40 different cancer genes are represented in US Food and Drug Administration (FDA)-approved targeted therapeutics and detected by FDA-mandated diagnostic assays that use cytogenetics, PCR, microarrays, or Sanger sequencing to detect mutations. High-throughput sequencing can, in principle, detect all of these mutations with sufficient sensitivity, and, thus, sequencing of panels of therapeutically targetable genes has emerged as an entry
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Sequencing extended panels of cancer genes
Following promising studies to identify hot-spot mutations and single-nucleotide variants (SNVs) in specific genes, extended panels have been incorporated into recent analyses to detect SNVs, copy number aberrations (CNAs), structural rearrangements, and gene fusions. For example, the Memorial Sloan Kettering (MSK)-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) project used targeted sequencing of exons and selected introns of 341 cancer genes 27 and was expanded to 410 genes in a follow-up study 28 . Likewise, Foundation Medicine (Cambridge, MA, USA) sequenced exomes of 287 cancer-related genes together with intronic sequences from 19 genes involved in rearrangements or other aberrations 29 ; later, this was expanded to 315 exomes, together with intronic sequences from 28 genes. Perhaps one of the largest such efforts is the University of Michigan's 'MI_Oncoseq' program, where exomes for a panel of 1,700 cancer-related genes are captured for parallel sequencing of tumor and germline DNA (C.K.-S., A.M.C., and colleagues) 30 .
Sequencing gene panels helps identify a broad range of cancerassociated aberrations but retains the advantages of cost effectiveness, fast output, and the use of limiting amounts of starting material, all preferred attributes for the application of NGS in clinical practice. Hand in hand with increasing participation of patients and cancer centers, more patients are being matched with therapeutics that are targeted for specific molecular aberrations but not yet approved for pan-cancer treatment by the FDA. The American Society of Clinical Oncology (ASCO) has capitalized on these findings by launching a Targeted Agent and Profiling Utilization Registry (TAPUR) study (https://www.tapur.org/), which is a non-randomized clinical trial that will formally test the potential utility for off-label targeted therapies in cancer.
Exome or genome sequencing for individuals
The data from gene panel sequencing are indeed limited by the selection of genes in the panel but may also be limiting in chromosomal ploidy aberrations, arm level gains or losses, and unknown or new 'cancer genes' . Whole-exome capture sequencing analyzes the complete coding portion of the genome and provides a comprehensive genomic profile of aberrations in protein coding genes, arguably at relatively reduced coverage at individual loci; it is also costlier, takes longer, and is more resource and analysis intensive than using a limited panel of sequences.
Whole-exome or genome sequencing has been particularly informative for analyzing exceptional therapeutic response or resistance. For example, a metastatic bladder cancer patient who showed an exceptional response to the mTOR (the mechanistic target of rapamycin) inhibitor everolimus in a clinical trial categorized as 'failed' , NCT00805129, showed loss-of-function mutations in tuberous sclerosis complex gene 1 (TSC1) and neurofibromatosis type 2 gene (NF2). These genes are associated with mTOR pathway activity but were not previously associated with therapeutic response 31 . Similar mutations were identified in additional bladder cancer patients, who may also potentially respond to everolimus. Similarly, activating mutations in mTOR were identified in a patient who was an exceptional responder to everolimus and pazopanib 32 ; mutation in DNA repair protein RAD50, associated with loss of ataxia telangiectasia mutated gene (ATM) signaling 33 , was found in an exceptional responder to treatment with checkpoint kinase 1 (CHK1) inhibitor in combination with DNA-damaging agent irinotecan (Camptosar); and an exceptional response to an insulin-like growth factor 1 receptor (IGF-1R)-specific antibody was observed in a patient with ALK fusion-positive lung cancer 34 .
The underlying mechanisms for drug sensitivity or resistance are not always straightforward. For example, a pre-treatment tumor sample from a patient with stage IVA head and neck squamous cell carcinoma, who showed a near-complete histologic response to erlotinib (Tarceva) revealed no EGFR alterations as expected; instead, the tumor harbored an activating mutation in mitogen-activated protein kinase 1 (MAPK1) (p.E322K) that enhanced EGFR phosphorylation, resulting in erlotinib sensitivity 35 . Furthermore, sequencing of BRAF (v-raf murine sarcoma viral oncogene homology B1 gene)-mutant colorectal cancer biopsies before and after treatment with RAF inhibitors, identified KRAS amplification and overexpression in one patient, BRAF amplification and overexpression in another case, and a putatively activating mutation in the RAF family protein, ARAF p.Q489L, together with a resistance mutation in MAP2K1 p.F53L, in a third patient 36 . In a study to investigate markers associated with resistance to PD-1 immune checkpoint blockade in metastatic melanoma, whole-exome sequencing identified loss-of-function mutations in JAK1 (Janus kinase 1 gene), JAK2 (Janus kinase 2 gene), and B2M (beta-2 microglobulin gene) 37 .
Remarkably, a review of ten years of unpublished data from clinical trials by the NCI Cancer Therapy Evaluation Program has estimated that as many as 10% of patients were "exceptional responders" in phase 2 clinical trials of therapies that failed to receive FDA approval 38 . NCI launched the Exceptional Responder Program in 2014 to systematically reanalyze these trials with the aim of identifying new combinations of aberrations and therapeutics [38] [39] [40] . These analyses will require comprehensive whole-exome/genome analyses.
Despite evidence of utility, clinical sequencing programs have been deterred from application of whole-exome or whole-genome sequencing in routine clinical settings owing to the extra time, cost, resources, data storage, and analysis requirements. Instead, most sequencing centers sequence targeted panels that can be gradually expanded to incorporate additional genes and sequences of interest.
Precision oncology in routine clinical practice Sequencing-based clinical precision oncology programs have only recently been implemented and only a few have reported results so far. Among these representative programs, the University of California, San Diego (UCSD) Moores Cancer Center reported findings from the Profile Related Evidence Determining Individualized Cancer Therapy trial (PREDICT-UCSD; NCT02478931), wherein 347 patients with advanced solid malignancies were analyzed using Foundation Medicine exon-capture panels; of these, 87 patients (25%) were treated with a matched therapy and had a slightly longer median progressionfree survival compared with unmatched patients 25 . Mentioned above, the MSK-IMPACT 28 project described an exome capture-based 410-gene panel assay for solid cancers (with matched germline samples), wherein >10,000 patients with advanced cancer have been analyzed so far, with up to 11% of patients enrolled in genomically matched clinical trials 30 . The Memorial Sloan Kettering Cancer Center (MSKCC; New York) study prioritizes the use of targeted gene panels over whole-exome sequencing to maximize throughput and depth of coverage, and, additionally, to reduce costs.
The precision oncology program at the MD Anderson Cancer Center 26 reported sequencing results from 1,200 patients with advanced cancer, in which targeted sequencing of 201 genes or r e v i e w hot-spot mutation analysis of 11 to 50 genes were performed. At least one alteration in a potentially actionable gene was noted in 945 patients (79%) using the larger panel, compared with only 527 patients (44%) with hot-spot testing, supporting the use of large panels in routine clinical tests 41 . Weill Cornell Medical College in New York applied whole-exome sequencing in routine clinical practice, analyzing tumor-normal pairs of 97 metastatic cancer patients, with informative aberrations observed in 91 patients, of whom 5 went on to receive targeted therapies 42 . These early reports are indicative of the immense interest in the community to deploy precision oncology in routine cancer care, even as questions of cost, choice of optimal analytical platforms, standardization of the assays and reporting metrics, and potential efficacy of these efforts continue to be deliberated.
Integrative clinical sequencing in precision oncology
Combining exome sequencing of germline and tumor tissue DNA with RNA sequencing can interrogate a wide array of somatic and germline aberrations in parallel ( Fig. 2) and has been effective in discovering actionable aberrations in osteosarcoma 43 , urothelial carcinoma 44 , nonsmall cell lung cancer (NSCLC) 45 , endometrioid endometrial carcinoma (EEC) 46 , melanoma 47, 48 , and a case of Sézary syndrome 49 .
The University of Michigan (Ann Arbor, MI, USA) has implemented an integrative clinical sequencing program called MI_Oncoseq 50 for all-comer advanced cancer patients with diverse tumor types in a hospital and academic setting. Participation in clinical sequencing is initiated by the attending physician (Fig. 3) . After written informed consent is obtained from the patient, tumor biopsy and a blood or buccal swab are used to extract DNA and RNA, which are sequenced and analyzed. These data are analyzed for potential clinical relevance and actionability through an extensive literature survey of the disease, tumor aberrations, and potential therapeutic matches (Box 1). Finally, the integrative molecular analyses are summarized and any therapeutic insights discussed at a multidisciplinary tumor board meeting attended by the referring physician and various key personnel involved in the entire MI_Oncoseq process. A final summary clinical report with clinical recommendations is provided for the referring physician. From start to finish, this process takes three weeks in most cases.
Similar to the multidisciplinary cancer conferences ('tumor boards') that are currently mandated by the American College of Surgeons to facilitate access to expertise in evolving technologies in accredited cancer programs 51, 52 , integrative precision oncology programs have implemented multidisciplinary molecular tumor boards to discuss molecular findings and make clinical recommendations [53] [54] [55] [56] [57] [58] . MI_Oncoseq has implemented a multidisciplinary precision medicine tumor board (PMTB) comprising oncologists, cancer geneticists, genetic counselors, pathologists, biologists, bioinformaticians, bioethicists, clinical study coordinators, and ad hoc experts 50, 59 . Underscoring the vital importance of tumor boards in driving clinical sequencing efforts, and the need for standardized practices, ASCO is considering the development of a web-based, interactive molecular tumor board for educational purposes 60 .
At MI_Oncoseq PMTB meetings, individual cases are presented with clinical history, family history, tumor pathology and histopathology of specimens used for sequencing, summary details of sequencing libraries, quality control metrics of sequencing data, and estimation of tumor content based on the proportion of copy neutral heterozygous SNVs in the data (Box 1). This is followed by a detailed assessment of germline and cancer aberrations, potential clinical implications thereof, and proposed follow-up action items, all topics expanded upon in the next sections. Clinical coordinators then continue to track the clinical course of patients in consultation with the clinicians.
Germline DNA sequencing of cancer patients Sequencing of the cancer patient's germline DNA in parallel with tumor DNA has typically been undertaken to filter out germline polymorphisms from the somatic mutation data. However, identification of germline mutations in cancer-predisposing genes has critical implications for the patient and their families, prompting active screening, surveillance, prophylactic actions, and preventative lifestyle adjustments (Supplementary Table 1 ). For example, germline aberrations in DNA repair pathway genes BRCA1/2 (breast cancer 1/2 early onset gene), as well as ATM, CHEK2 (CHK2 checkpoint homology gene), and PALB2 (partner and localizer of BRCA2), have been associated with responsiveness to poly (ADP-ribose) polymerase (PARP) inhibitor therapies in ovarian, breast, and prostate cancers [61] [62] [63] [64] [65] . Similarly, germline mutations in mismatch repair pathways have been associated with responsiveness to immune blockade therapy 66 .
Furthermore, several recent cancer sequencing studies have observed a high frequency of germline mutations in cancer predisposition genes among sporadic cases with no family history of cancer, as suggested by a recent analysis of single-nucleotide polymorphism (SNP) array-based r e v i e w genome-wide association studies (GWAS) 67 . Also, among 4,034 TCGA (The Cancer Genome Atlas) cancer cases, representing 12 cancer types, rare germline truncations were noted in 114 cancer-susceptibility-associated genes, spanning 4% of acute myeloid leukemia (AML), 11% of stomach cancer, and up to 19% of ovarian cancer cases 68 . Not surprisingly, the germline mutation burden is high among pediatric cancer cases, where ~10% of the cases had notable germline findings in two studies 59, 69 . Incidentally, pathogenic germline mutations have been noted in a substantial proportion of sporadic pediatric cancer cases 69 . Focusing on germline variants, the LCCC1108/UNCseq_ (NCT01457196) study involving 439 pediatric and adult cancer patients unselected for hereditary cancer predisposition identified 4.3% of the patients with pathogenic germline variants 70 . In addition to these pancancer studies, up to 11.8% of advanced prostate cancer cases were found to harbor pathogenic germline alterations 53, 71 , with a significantly higher rate of germline mutations observed in metastatic cases compared to patients with localized tumors 72 . The frequent germline mutations observed in sporadic cancer patients argues for germline sequencing to be included as an integral part of routine clinical sequencing workflows, not restricted to patients with family history of cancer.
A list of clinically actionable germline variants commonly identified can be found in Supplementary Table 1, and Supplementary Table 2a details current clinical trials centered on germline aberrations. In the MI_Oncoseq workflow, germline variants referenced as pathogenic in ClinVar are reviewed by a clinical geneticist for implications for disclosure to the patient/family. Additionally, integration of the germline and somatic sequencing data helps define mutations showing loss-of-heterozygosity (LOH) in the tumor that may be missed if only the tumor was sequenced.
Copy number aberrations. Exome capture data from paired tumor and normal DNA are used to determine exome-wide somatic copy number aberrations by comparing the depth of coverage at all of the individual exons analyzed followed by segmentation analysis along the lines used for array comparative genomic hybridization (cGH) data, creating high-resolution copy number profiles, while circumventing technical variations 73 . The genome-wide copy number profile at exon-level resolution is plotted in a visually intuitive, color-coded linear chromogram to evaluate a variety of copy-number aberrations, including focal or wider amplifications, deletions, copy losses, or gains. Interestingly, in addition to identifying susceptibilities to classical therapies, aneuploidy and the burden of copy number loss have been associated with responsiveness to immunotherapy 74, 75 . These findings add another layer of potentially actionable information available from CNV analyses, and one that might be missed in highly selective targeted gene panels. Analysis of data from cancer samples with low tumor content and extreme ploidy changes, however, continues to present analytical challenges still awaiting satisfactory resolution.
Somatic SNVs/indels. Analysis of somatic mutations in cancers, many of which define canonical driver aberrations and therapeutic targets, is likely the most informative output of clinical sequencing (Supplementary Table 2b ). Pairwise analysis of tumor DNA samples compared with germline sequencing data helps distinguish germline polymorphisms from somatic mutation calls. At MI_Oncoseq, we also determine the variant allele fraction (the ratio of variant/reference reads), zygosity mutations, total number of somatic mutations, and mutation burden (number of mutations/Mb; considered in the context of the published range of cohort-specific mutation numbers in TCGA data [76] [77] [78] and similar data from our compendium of >1,700 advanced cancer cases 30 ).
To identify functionally relevant variants, we highlight the hotspot, activating, or loss-of-function mutations based on recurrence in the COSMIC (Catalogue of Somatic Mutations in Cancer) database, as well as stop/gain SNVs or frame-shifting insertions/deletions. Mutations close to hot spots or involving functionally critical domains are also noted. Published literature on key mutations is
Box 1 Precision Medicine Tumor Board
The actionable germline and somatic findings along with clinical implications and therapeutic options for individual cases are discussed in the context of the following background information. Please refer to the main text of this article for detailed discussion of the clinical data analyses. Clinical history. Brief clinical histories of the patients, from the time of cancer diagnosis, key clinical signposts, prior therapies, responses, status of imaging, histological and/or molecular markers, history of response to therapies, disease progression, leading up to the details of biopsy of the clinical sequencing, are noted. Family history. Incidences of cancer in the family of patients are documented by a clinical geneticist to assess each case as likely familial or sporadic. Detailed in the main text, in a subset of cases, pathogenic germline variants are noted irrespective of a family history of cancer. Pathology. Hematoxylin-and-eosin-stained sections of the tumor-biopsy specimens to be used for sequencing are assessed by a pathologist for histopathology of the tumor specimen as well as estimation of tumor content. Tissue blocks adjudged to represent the highest tumor content are used for making sequencing libraries. Samples for sequencing libraries. DNA and RNA are simultaneously isolated from the same tumor tissue sections to ensure concordance of the samples used for genomic and transcriptomic analyses. DNA for germline sequencing is typically derived from blood samples in the case of solid cancers and from buccal swabs for hematological malignancies. Although frozen tumor samples are preferred starting material for sequencing DNA or RNA, recent technical and analytical improvements have facilitated routine use of formalin fixed-paraffin embedded (FFPE) samples for clinical sequencing 29, 53, 59, [178] [179] [180] . Quality of RNA sequencing is particularly sensitive to the integrity of the starting RNA material. To improve the information content of RNA-seq using suboptimal quality RNA samples, we have developed a transcriptome capture methodology using standard exome capture probes 181 . Quality control sequencing data. Based on the guidelines proposed by the Standardization of Clinical Testing (Nex-StoCT) workgroup 182 , quality metrics of the sequence data are assessed before launching into mutation/gene expression analyses. Exome capture data from tumor samples with ~400× average coverage, matched with normal (blood or buccal) samples with ~300× average coverage, are considered optimal for analyses. The tumor content is estimated using a set of high-quality SNV candidates on 2-copy genomic regions 59 . Sequencing quality is determined by several standardized criteria 30 , and sequencing libraries failing any of the quality metrics are flagged and factored during biological analysis and interpretation of the data.
The level of expression of mutant genes often provides additional supportive evidence for the likely effect of the mutations. For example, splicing mutations show intron retention (e.g., CBL (Casitas Blineage lymphoma proto-oncogene), NF1, ATM, and TP53) or exon skipping (e.g., MET (hepatocyte growth factor receptor) gene), and in-frame expression of large indels (e.g., NOTCH1 (Notch homolog 1, translocation-associated gene), FOXA1 (forkhead box A1 gene), EGFRvIII or its variants) can occur. Additionally, a locus sometimes shows chromosomal gain or amplification, but no corresponding increase in expression levels of resident genes.
Mutational signatures. Analysis of the patterns of somatic aberrations in cancers has emerged as a source of clinically actionable insights. Distinct patterns of genome-wide mutations in trinucleotide units observed in genome/exome sequencing data from diverse cancers have helped define signatures of somatic mutations characteristic of different tumor types, defective DNA recombination/repair pathways, and those that provide insights into the mechanism of carcinogenesis through external exposures, such as UV radiation, tobacco, or alkylating chemotherapeutics like temozolomide [76] [77] [78] [79] [80] [81] (http://cancer.sanger. ac.uk/cosmic/signatures). Some hypermutated cancers, such as UVinduced malignant melanoma, have shown dramatic responsiveness to immunotherapies, associated with expression of neo-antigens by the cancer cells as a result of their increased mutational load [54] [55] [56] [57] [58] 82 . Additionally, cases with a microsatellite instability signature, typically but not always accompanied with loss-of-function mutations in mismatch repair (MMR) genes 83 , have been associated with responsiveness to immune checkpoint inhibitor therapy 66, 84 . Along similar lines, the signature of homologous repair deficiency 77 , typically associated with mutations in BRCA1, BRCA2, and other Fanconi anemia pathway genes 85 , is also observed in some sporadic cancers said to display 'BRCAness' 86, 87 . Similar to BRCA mutation carriers, cancers displaying BRCAness have been associated with responsiveness to platinum-based therapies as well as PARP inhibitors [88] [89] [90] [91] [92] [93] .
In addition to informing therapeutic avenues, mutational signatures of individual cases also help corroborate or qualify challenging diagnoses (e.g., a cancer of unknown primary origin showing a distinct smoking signature, characteristic of lung cancer 76 ) or glean insights into specific mechanisms of tumor progression (e.g., APOBEC signature 94, 95 , signature of temozolomide treatment). Notably, whole exome or larger exome capture panels are better suited for mutation signature analyses; for more selective targeted panels, it may be useful to incorporate targeted probes to query for therapeutically informative signatures, such as microsatellite instability and BRCAness.
Precision immunotherapy. In recent years, several different immunotherapy approaches have shown promise in the clinic. Immune checkpoint blockade targeting CD28/CTLA4 (cytotoxic T-lymphocyte-associated protein 4) or PD-1/PD-L1 (programmed cell death receptor 1/programmed cell death receptor ligand 1) has emerged as a promising therapeutic approach across diverse cancers 76, [96] [97] [98] [99] . However, as only small subsets of patients benefit from the treatment, genomic or transcriptomic markers to predict response in genomes or transcriptomes are highly sought after (Fig. 2b) .
Neo-antigen peptide vaccines based on individual cancer mutanomes (all mutant protein-coding sequences identified by high-throughput sequencing) have shown efficacy in protecting and treating the tumor in xenograft models 55, 100 and are being tested in several ongoing clinical trials (e.g., NCT02287428, NCT02950766, and NCT01970358).
Adoptive cell therapy uses ex vivo-expanded tumor-infiltrating lymphocytes (TILs), based on identification of an immunogenic neo-antigen showing high-affinity binding to the patient's major histocompatibility complex (MHC) antigen 101, 102 . Unfortunately, the excitement of promising responses to immunotherapy across several cancer types is tempered by a relatively small percentage of patients achieving dramatic, durable responses and multiple modes of primary or acquired resistance 103 .
Several markers of sensitivity, response, and resistance to the various immunotherapies have been identified, including the level of tumor neoantigens 17, [104] [105] [106] , tumor genomic aberrations, gene expressions, profiles of TILs, and T-cell receptor diversity 107 . Gene expression analysis tools like CIBERSORT 72 and TIMER 96 help define the profile of TILs from tumor RNA-seq data.
Transcriptome sequencing in the clinic
Many clinical sequencing workflows currently do not involve RNA sequencing of the tumor samples, possibly due to additional requirements of technical and analytical bandwidth as well as cost and time constraints. However, we and others have observed that a parallel analysis of genomic and RNA-seq data helps to identify expressed gene-fusions (including inactivating rearrangements involving tumor suppressors) and splicing aberrations, and enables the detection of pathogenic viruses. Expression signatures of tumor biomarkers can help confirm or corroborate tumor diagnoses, and in cases of tumors of unknown primary origin, help predict the likely tissue and/or lineage of origin. Gene expression profiles also help assess the functional status of critical pathways. For example, expression levels of androgen receptor (AR) pathway genes, like ACPP (prostatic acid phosphatase gene), KLK2/3 (kallikrein-related peptidase 2/3 gene), SLC45A3 (solute carrier family 45, member 3 gene), and TMPRSS2 (transmembrane protease, serine 2), help assess the status of AR pathway regulation in prostate cancer samples, irrespective of the status of AR gene or level of AR transcript. Similarly, specific mutations in cancer-associated pathway genes, like those of the NOTCH, WNT-beta-catenin, SHH (sonic hedgehog gene), and HIPPO pathways, can be assessed for functional consequences in terms of expression levels of their downstream target genes.
As mentioned in the previous section, RNA sequencing data has also found application in defining the expressed mutanome of cancer samples to nominate candidate neo-antigens for immunotherapy 55, 58, 97 . In an interesting analysis, Newman et al. 72 have defined gene expression patterns corresponding to various cell types in cancer tissues, including tumor-infiltrating immune cells, providing a powerful tool to assess the immune-reactive status of different tumors. A fortuitous application of RNA-seq is also in highly sensitive and specific detection of cancer virus and/or pathogens in tumor tissues, such as human papilloma virus (HPV16/18), human herpesvirus-4 (EBV), human T-lymphotropic virus (HTLV), and Merkel cell polyoma virus, which is important for the application of immunotherapy and cancer virus vaccines. These diverse observations afforded by RNA-seq provide critical diagnostic and therapeutic insights that are not available with DNA sequencing alone 98, 99 .
Gene fusions.
A wide variety of gene fusions serve as diagnostic and prognostic biomarkers, as well as therapeutic targets, for several types of cancer 108, 109 . RNA-seq data are particularly useful in not only identifying gene fusions, but also providing an assessment of expression levels of the fusion transcripts. In MI_Oncoseq, we have identified ETV6-ABL1 (ETS variant gene 6-Abl1 fusion) 59 , NAB2-STAT6 (NGFI-A binding protein 2-signal transducer and activator of r e v i e w transcription 6) 110 , and various FGFR (fibroblast growth factor receptor gene) fusions 111 using RNA-seq. Detection of chimeric RNAs involving tumor suppressor genes, showing loss of open reading frame/functional domains, although a relatively underexplored area of investigation, is another clinically informative application of RNA sequencing data analyses (C.K.-S., A.M.C., and colleagues) 30, 53, [109] [110] [111] . Apart from gene fusions, RNA-seq can provide evidence of alternative splicing aberrations (AR-V7 (androgen receptor variant 7) in prostate cancer 112, 113 ), novel isoforms with therapeutic implications (ALK alternative transcription initiation, ATI 114 ), or exon-skipping events, including exon 14 skipping in MET, reported in subsets of lung cancer 115, 116 . The biomarker analysis is particularly useful in cases of diagnostically challenging specimens, as well as advanced cancer cases with unknown primary tissue of origin [117] [118] [119] [120] [121] . Besides expression of tissue-specific biomarkers, we nominate the tissue type of tumors of unknown origin with a machine-learning algorithm 30 , using a bootstrap aggregation of six different prediction models trained on RNA-seq data from 33 primary tumor types in TCGA and normal tissue expression data obtained from GTEx (the Genotype Tissue Expression project), TCGA, and the Human Proteome Atlas, based on a modification of a method by Vincent et al. 122 .
Gene expression analyses.
Finally, some therapeutic target genes show exceedingly high outlier expression in certain samples, with or without an observed genomic aberration, and may represent therapeutic avenues not derived from obvious genomic aberrations. For example, outlier expressions of MET in a case of esophageal carcinoma, ROS1 (c-ros oncogene 1 receptor tyrosine kinase) in a non-small cell lung cancer, and RET (Ret tyrosine kinase proto-oncogene) in a neuroendocrine carcinoma of the larynx were found to represent potential therapeutic targets in our study 30 .
Clinical report enables actionable recommendations
All of the potentially actionable or informative molecular aberrations in a patient's tumor or germline discussed in PMTB meetings are summarized and submitted to the attending physician with specific recommendations relating to the individual cases. While the essential report format is similar across different tumor sequencing programs, specific details vary based on types of analyses. Table 1 provides examples of all of the different aspects of the germline, somatic, and/or expression data represented among the different cases analyzed. It is important to emphasize the critical importance of integrative analyses, as a singular focus on exome sequencing would likely miss many of the actionable observations revealed through systematic integration. A formal comparison of the different modalities may be moot to consider for future programs.
Outlook for clinical sequencing in cancer
Currently, clinical sequencing programs largely focus on exome capture sequencing instead of sequencing the whole genome. However, it is increasingly apparent that recurrent aberrations in non-exonic regions of the genome, including promoters, enhancers, other regulatory elements, protein/RNA binding sites, intergenic loci of lncRNAs, and miRNAs, need to be reconciled for a fuller assessment of cancer genomic aberrations. The recent discovery of hot-spot mutations in the TERT (telomerase reverse transcriptase) promoter that lead to aberrant reactivation of telomerase was based on sequencing of a genomic locus defined by GWAS studies of familial melanoma 123 as well as whole-genome sequencing of melanoma samples 124 . This was followed by its detection in urothelial carcinoma 125 , brain cancer 126, 127 , and thyroid cancer 128 using amplicon sequencing or targeted TERT promoter sequencing 129 . Fortuitously, the TERT promoter mutation hot spots happen to be located just upstream of the first exon and are, thus, captured by whole-exome sequencing [130] [131] [132] . This example highlights the realm of somatic aberrations located outside the regions typically included in exon-capture panels that are not being actively targeted by exome capture. Indeed, using whole-genome sequencing data from TCGA and elsewhere, recurrent mutations in upstream regulatory elements have been described in DPH3 (diphthamide biosynthesis 3 gene), PLEKHS1 (pleckstrin homology domain-containing, family S member 1 gene), WDR74 (WD repeat domain 74 gene), and SDHD (succinate dehydrogenase complex subunit D gene) 104, 105 .
Further highlighting the importance of gene regulation in cancer, sequencing efforts have revealed numerous aberrations in chromatin-related genes 106,133-138 across diverse tumor types. As an example, almost all cases of pediatric malignant rhabdoid tumors are characterized by the singular loss of SWI/SNF chromatin remodeling complex gene SMARCB1 (refs. 106,134,139-141) . Similarly, almost 60% of bladder tumors show mutations in epigenetic modifiers 142, 143 , and a majority of pediatric diffuse intrinsic pontine gliomas harbor mutations in histone H3A/H3B [144] [145] [146] [147] . Therapeutic approaches targeting epigenomic aberrations have primarily included DNA demethylation (DNA methyltransferase) inhibitors, such as azacytidine, which is FDA-approved for use in myelodysplastic syndromes, and histone deacetylase (HDAC) inhibitors, such as vorinostat (suberoylanilide hydroxamic acid; SAHA) and panobinostat, which are FDA-approved for cutaneous T-cell lymphoma and multiple myeloma, respectively. In this context, it is expected that high-throughput epigenomic profiling integrated with clinical sequencing will illuminate a mechanistic understanding of the molecular ramifications of aberrant DNA modification pathways in cancer to help inform wider application of precision therapeutic approaches targeting other epigenomic aberrations 148, 149 . Integration of methylome sequencing to profile epigenomic aberrations with proteomics will help further expand the field of actionable cancer aberrations.
Another exciting area of development with potential for immediate clinical impact is sequencing of minimally invasive 'liquid biopsies' , including blood, cerebrospinal fluid, or urine from cancer patients. Analysis of circulating tumor cells, exosomes, or cell-free circulating tumor DNA/RNA (ctDNA/RNA) transcends the issues of sampling bias, tumor heterogeneity, and metastases not amenable to biopsy, and can help assess disease progression, response to therapy, emergence of resistance, or new therapeutic targets [150] [151] [152] . Marking a tangible advance in this arena, the FDA has recently approved detection of EGFR mutations in the ctDNA from blood of lung cancer patients r e v i e w Table 1 Integrative sequencing provides an array of actionable observations (continued) r e v i e w as a companion diagnostic assay for erlotinib treatment 153 . The next frontier may be sensitive and robust detection of panels of 'hot-spot' aberrations in liquid biopsies 154, 155 . Apart from genomic analyses, integration of gene-expression signatures with genes and small molecules 156 , metabolomic assessments 157 , and proteomic interactome maps 158 represent areas of future development. However, functional characterization and translation of these data to inform clinical decisions could be more challenging than matching somatic aberrations with therapies.
Evaluation of workflows for integrative precision oncology
Cancer is a long-term disease, which means that sequencing a tumor once (i.e., current practice) provides only a snapshot of a dynamic process. As sequencing becomes routine, sequencing of tumor biopsies at diagnosis, resection, progression, and after therapy will help generate a more complete picture of cancer development. Common examples of treatment-emergent alterations that could be detected by sequencing include the acquisition of mutations in the ligand binding domain of ESR1 following aromatase inhibitor therapies in breast cancer, AR amplification and mutations in prostate cancers following endocrine deprivation therapy, and mutations in receptor tyrosine kinases following treatment with small-molecule inhibitors of these enzymes. It is also important to determine if multiple targeting avenues are potentially available at an early stage in cancer. Eventually, clinical sequencing could supplant individual gene-centric assays. First, we need evidence that sequencing provides a more sensitive and reliable detection modality than FDA-approved diagnostics. It is feasible that sequencing could serve as a primary diagnostic modality, along with histopathology and radiographic imaging.
Currently, the reported turnaround time for clinical sequencing analyses ranges from two to six weeks. Turnaround time is two weeks at Foundation Medicine, a month or less at MSKCC for the MSK-IMPACT study 28 and Clinical Genomics Program, Taussig Cancer Institute (Cleveland), and Cleveland Clinic 159 , and ten days to six weeks for the University of Michigan MI_Oncoseq 59 study. This time frame may need to be further shortened to one to two weeks for routine clinical application.
Determining the efficacy of integrative pipelines is confounded by the fact that typical patients availing themselves of clinical sequencing, such as at MI_Oncoseq, have late-stage, advanced disease and have received, and often failed, multiple therapies, have maximal mutational burden, including therapy-resistant mutations, and have more or less arrived at a therapeutic cul de sac. In this setting, despite identification of compelling therapeutic leads, the patient's physical condition often makes them ineligible for trials or incapable of tolerating treatment. Unfortunately, in several cases, within a month of providing samples for analysis, patients moved to hospice care, were lost to follow-up, or died.
Several unforeseen circumstantial contingencies can also mitigate the potential benefits from the sequencing findings. Patients enrolled for a clinical trial following a specific therapeutic indication after sequencing analysis may get placed on the control arm of the study, denying them the opportunity to benefit from the specific information about their cancer; several such cases occurred in the gene fusion study at the University of Michigan, UMCC 2012.022. Having varying eligibilities for clinical trials across different institutions is also problematic; for example, activating mutations in PIK3CA (phosphoinositide 3-kinase catalytic alpha subunit gene) are common in breast cancer, but patients displaying a hot-spot activating mutation in PIK3CA, being treated at the University of Michigan, cannot enroll in the ongoing PI3Ki SIGNATURE trial, as it excludes breast and prostate cancer. The need to negotiate with pharma and insurance companies to consider r e v i e w sequencing results as rationale for providing drugs for off-label use on compassionate grounds is also a constant hurdle to overcome.
Unlike the rigorous assessment that novel drugs or therapeutics are subjected to, precision oncology is fairly new and empirical evidence of its effectiveness remains equivocal. A systematic, multicenter randomized, controlled phase 2 trial (SHIVA; NCT01771458) directly comparing the efficacy of off-label molecularly targeted therapies based on tumor molecular profiling with conventional therapy, observed no significant improvement in progression-free survival in the targeted therapy group in a cohort of heavily pre-treated cancer patients 11, 160 . Elsewhere, the NCI initiated comparative effectiveness research (CER) to systematically assess the efficacy of cancer genomics and precision medicine. Based on early findings of seven research studies and a follow-up workshop, they reported "insufficient evidence of clinical utility of precision medicine in translating genomic discoveries into clinical practice" 161 . Representing a skeptical position on the efficacy of precision oncology, the hematologist-oncologist Vinay Prasad at Oregon Health and Science University recently weighed the rather few reports of exceptional responses to targeted therapies against a preponderance of failed attempts. Given the paucity of randomized clinical trials formally testing the metrics of success, the very premise and promise of precision oncology was questioned 162, 163 . On a more positive note, in a recent prospective clinical trial to evaluate the clinical benefit of highthroughput genomic analyses (MOSCATO 01), actionable molecular alterations were identified in up to 48% of the cases analyzed (411 of 843 patients), of which 199 patients could be treated with a matched targeted therapy 164 . Of the successfully screened patients, 7% were assessed as having benefited from this approach in terms of progression-free survival on matched therapy as compared with previous therapy.
Box 2 Community resources and data repositories serving precision oncology
High-throughput, data-intensive applications of precision oncology have produced a plethora of databases, repositories, and online portals, catering to various distinct niches that are extensively used in clinical sequencing data analyses ( Table 2) . These include repositories of primary sequencing data, such as the Sequence Reads Archive (SRA; https://www.ncbi.nlm.nih.gov/sra) and the Database of Genotypes and Phenotypes (dbGAP; https://www.ncbi.nlm.nih.gov/gap), which is hosted by the US National Center for Biotechnology Information (NCBI) and provides high-throughput genomic/transcriptomic/methylome and other data relating to human genotypes and phenotypes. Public databases of germline variations, such as 1000 Genomes Project and the Exome Aggregation Consortium (ExAC; http://exac.broadinstitute.org/), provide very useful compendia of genetic polymorphism in the human population. Of these, the 1000 Genomes Project, concluded in 2015 (refs. 183,184) , provides a comprehensive reference of common human genomic variations compiled from 2,504 individuals representing 26 distinct populations worldwide. ExAC is an even more expansive public resource that aggregates exome sequencing data from multiple large-scale sequencing projects (including the 1000 Genome Study), spanning a total of 60,706 unrelated individuals from various disease-specific and population genetic studies. Reference databases with curated, annotated information on pathogenic germline aberrations associated with cancer include Online Mendelian Inheritance in Man (OMIM; https:// www.omim.org/) 185 , Leiden Open Variation Database (LoVD; http://www.lovd.nl/3.0/home) 186, 187 , and NCBI ClinVar (https://www.ncbi. nlm.nih.gov/clinvar/) 188 . Primary cancer sequencing data repositories include The Cancer Genome Atlas (TCGA), International Cancer Genomics Consortium (ICGC), and University of California Santa Cruz (UCSC) Cancer Genomics Browser. These provide valuable references for assessing recurrence of rare somatic variants, estimation of tumor-type-specific mutation burden, mutation-signature analyses, and comparisons of gene expression, among other applications.
Data visualization portals include cBioportal for TCGA data (http://www.cbioportal.org/) and UCSC Xena Browser (http://xena.ucsc.edu/) for data across multiple consortia. The UK Sanger Center (Hinxton) hosts a compendium of somatic aberrations in cancer (COSMIC; http://cancer.sanger.ac.uk/cosmic); and the NHGRI/Washington University hosts the Turnkey Variant Analysis Project (TVAP; http://tvap. genome.wustl.edu/overview/) that provides multiple popular open-source bioinformatics tools for detection, interpretation, and visualization of high-throughput sequencing data, and a database of curated mutations (DoCM; http://docm.genome.wustl.edu/).
Finally, to explore models of 'community' sharing of collective data repositories, the Genomic Data Commons (GDC; https://portal.gdc. cancer.gov/) program of NCI and Project Genomics Evidence Neoplasia Information Exchange (GENIE; http://www.aacr.org/Research/Research/Pages/aacr-project-genie.aspx#.Wh2YfnlryUk) launched by American Association for Cancer Research aim to foster unified data repositories that enable data sharing, analyses, and clinical interpretations across cancer genomic studies.
In our opinion, the metrics of the utility of precision oncology should be considered in the context of adding value to the standard of care, not apart from it. Much of what is the standard of care is already part of 'precision oncology' , including all the diagnostic and prognostic markers and targeted therapies matched with specific aberrations, currently in use. The latest high-throughput methodologies only help to scale up and expedite the assays over a broader range of cancers, providing access to molecular information that encompasses our collective knowledgebase. In this sense, the current forays in precision oncology would help generate an integrative knowledgebase of clinical, molecular, and therapeutic aspects of cancers that could usher in the next phase in the quest for a cancer cure.
Clinical sequencing data co-operatives As institutional efforts in precision oncology have grown, in numbers, as well as scope many initiatives to harness the information from collective data sets are underway. To formally test the suitability and efficacy of off-label use of targeted therapeutics, ASCO has launched a clinical trial (TAPUR) that will use genomic profiling data to match and test the utility of molecularly targeted cancer drugs outside the indications approved by the FDA and generate a registry of effective off-label usage 20 . In a different approach, the American Association for Cancer Research (Philadelphia) has launched the Project Genomics Evidence Neoplasia Information Exchange (GENIE), wherein seven independent clinical sequencing programs will pool their collective clinical, sequencing, treatment, and follow-up data to populate a public data repository reference. A joint research program undertaken by the National Human Genome Research Institute (NHGRI) and the NCI, called Clinical Sequencing Exploratory r e v i e w Research (CSER), is coordinating several research programs to help define optimal use and implementation of clinical sequencing tests 165, 166 . Under this conglomerate initiative, diverse issues, such as considerations for validation of NGS variants 167 , reporting germline findings [168] [169] [170] , diagnostic yield of tumor sequencing data 171 , classification of variants 172 , incorporation of sequencing data in electronic health records 173 , genetic counseling (A.M.C. and colleagues) 174 , and social and behavioral research 175 , are explored. Another cooperative effort is exemplified by the Oncology Research Information Exchange Network (ORIEN), comprising 11 US-based cancer centers sharing clinical, molecular, and therapy-related data to help match patients with appropriate clinical trials based on their molecular profile. Industry is also participating; the Medical Evidence Development Consortium (Med-C), a non-profit organization floated by Genentech (S. San Francisco, CA, USA), Roche (Basel, Switzerland), and Eli Lilly (Indianapolis), plans to develop uniform, standardized work flows for matching cancer mutations with targeted therapies, intuitive to clinicians and insurance companies. Similar initiatives are mooted in the international setting through the Clinical Cancer Genome Task Team of the Global Alliance for Genomics and Health 176 , as well as European data centers 177 .
Precision FDA was launched on December 15, 2015, to provide a private workspace in a public setting to make precision oncology studies available to users without access to big sequencing facilities (https://precision.fda.gov/). Users will have access to 'Genome in a Bottle' , a source of reference DNA for validating human genome sequences developed by the National Institute of Standards and Technology. Users will also be able to compare their results to previously validated reference results and share their results with other users, track changes, and obtain feedback (Box 2 and Table 2 ).
Conclusions
The incorporation of clinical sequencing analyses in oncology represents the culmination of a long-standing quest to systematically link tumor-specific molecular aberrations with mechanistically targeted therapies to inform individual patient treatment. It is envisaged that widespread access to the high-resolution molecular data on individual cancer cases, along with attendant clinical data, therapy details, and follow-up information, should help close the gaps in our understanding of cancer progression and pave the way for improved cancer treatments, as well as anticipate and overcome resistance to drugs. A sobering disclaimer is due at this stage; we are not there yet. 
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